Thromb Haemost 1999; 81(01): 50-53
DOI: 10.1055/s-0037-1614417
Review Article
Schattauer GmbH

Performance of a New Fibrin Monomer Assay to Exclude Deep Vein Thrombosis in Symptomatic Outpatients

Authors

  • Christoph Caliezi

  • Nadja Fünfsinn

  • Thomas Mauron

  • Iris Baumgartner

    1   From the Central Hematology Laboratory and Division of Angiology, Department of Internal Medicine, Switzerland
  • Irmela Sulzer

  • Martin Ulrich

    2   University Hospital, Inselspital Bern, and Division of Angiology, Department of Internal Medicine, Switzerland
  • Christoph Cottier

    3   Regionalspital Biel and Department of Internal Medicine, Regionalspital Burgdorf, Switzerland
  • Franziska Demarmels Biasiutti

  • Bernhard Lämmle

  • Walter A. Wuillemin

Weitere Informationen

Publikationsverlauf

Received02. Juni 1998

Accepted after resubmission01. Oktober 1998

Publikationsdatum:
08. Dezember 2017 (online)

Preview

Summary

In this study we prospectively assessed the reliability of a new fibrin monomer assay in 106 outpatients with clinically suspected deep venous thrombosis of the lower limb. According to the results of the objective tests and using different cut-off points we calculated the sensitivity, specificity and negative predictive value of the fibrin monomer assay. The prevalence of deep vein thrombosis was 44.3% (31.1% proximal, 13.2% distal). Using a cut-off level of plasma fibrin monomer of 3.5 μg/ml, a sensitivity, specificity and negative predictive value of 100% (95% CI: 94-100%), 35.6% (95% CI: 23-48%) and 100% (95% CI: 86-100%), respectively, were obtained. The exclusion rate was 19.8% (95% CI: 12-27%) of all referred patients. These accuracy indices compared favourably with the respective results of a routine D-dimer ELISA used for comparison. Conclusion: This new fibrin monomer assay appears to be a reliable method for the exclusion of deep vein thrombosis in symptomatic outpatients.